Regulus Therapeutics (RGLS) Stock Price, Quote & News

Company Profile

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. The company develops farabursen, an anti-miR oligonucleotide targeting miR-17 in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. It is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. The company has a licen...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 202 6300

Website: www.regulusrx.com

Address:

4224 Campus Point Court, Suite 210, San Diego, United States

BinaryLogic Jun. 26 at 2:38 AM

$VTYX $RGLS $VIGL

0 · Reply

BigBadBeethoven Jun. 25 at 6:09 PM

$RGLS well it looks like the sale went through as they got about 75% of the shares and they only needed one share more than 50%. So if you're holding it you're going to get $7 cash PLUS a CVR for every share you own. Just remember that the CVR is nontradable. You're going to have to hold it in your account or wherever until Farabursen hits it's milestones or the CVR expires at $0. I personally think that drug is going to be a BLOCKBUSTER and I actually wanted to HOLD RGLS, because I think 2 years down the line RGLS would have easily hit $100 if the buyout hadn't happened. But I didn't have enough shares to stymie their efforts. Did anybody here have enough shares to do that? Not a rhetorical question LOL

1 · Reply

JG101 Jun. 25 at 4:12 PM

$DTIL Increase my position by 30%. These small biotech stocks are easy to manipulate on good news. Look what happened with the good news $RGLS had: stock down over 30% and the best entry point I’ve ever seen (and used generously) in biotech. A few months later they went from below 1$ to 7$ with a 7$ CVR…

1 · Reply

DonCorleone77 Jun. 25 at 10:59 AM

$NVS $RGLS Novartis announces expiration of Regulus Therapeutics tender offer Novartis (NVS) announced that its previously announced tender offer by Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis, to acquire all of the outstanding shares of common stock of Regulus Therapeutics (RGLS), in exchange for $7.00 in cash per share, subject to any applicable withholding and without interest thereon, plus one contingent value right per share, representing the right to receive one contingent payment of $7.00 in cash, subject to any applicable withholding and without interest thereon, upon the achievement of a regulatory milestone, expired at one minute past 11:59 p.m., New York City Time, on June 24. Computershare Trust Company, N.A., the depositary for the offer, has advised that, as of the Expiration Time, approximately 56,374,397 Shares were validly tendered and not validly withdrawn pursuant to the Offer, representing approximately 74.49% of the issued and outstanding Shares immediately prior to the expiration time. The parties expect the transaction to close on June 25, promptly following the acceptance of all shares validly tendered and not validly withdrawn pursuant to the offer.

0 · Reply

Love_To_Learn Jun. 25 at 10:16 AM

$RGLS buyout went to u due to rejection from our end on our offer due to timing and special meeting that was held among many other reasons $PSTV !

0 · Reply

Thomas105 Jun. 25 at 5:58 AM

$RGLS https://www.cash.ch/news/top-news/novartis-kann-regulus-ubernahme-abschliessen-836879

0 · Reply

tradingcalendar Jun. 24 at 6:41 PM

M&A Regulus Therapeutics $RGLS is being acquired by Novartis $NVS via tender offer - Shareholders to receive $7.00 cash per share + 1 CVR - CVR is equal to a future potential value of $7.00 per share - Shares of RGLS to be delisted after the close of extended hours trading tonight More Information : https://www.sec.gov/Archives/edgar/data/1505512/000110465925052756/tm2515290-1_sc14d9.htm

0 · Reply

TwongStocks Jun. 23 at 8:00 PM

$RGLS NASDAQ Equity Corporate Actions Alert # 2025 - 325 Information Regarding the Tender Offer of Regulus Therapeutics Inc. (RGLS) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-325 The tender offer by Redwood Merger Sub Inc., an indirect wholly-owned subsidiary Novartis AG (NYSE: NVS) to acquire all of the outstanding common stock of Regulus Therapeutics Inc. (RGLS) is scheduled to expire one minute past 11:59 p.m. ET, on June 24, 2025, unless extended or terminated. The subsequent merger is tentatively scheduled to close prior to the market open on June 25, 2025. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on June 24, 2025. If the merger closes as planned, the stock will remain halted on the day of closing (June 25th) and will be suspended effective June 26, 2025. The merger consideration is $7.00 & one (1) contingent value right (CVR) for each share held.

0 · Reply

DonCorleone77 Jun. 23 at 10:33 AM

$NVS $RGLS Novartis announces expiration of HSR waiting period of Regulus offer Novartis (NVS) announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with Novartis' previously announced tender offer to acquire all of the outstanding shares of common stock of Regulus Therapeutics Inc. (RGLS), in exchange for $7.00 in cash per Share, subject to any applicable withholding and without interest thereon, plus one contingent value right per share, representing the right to receive one contingent payment of $7.00 in cash, subject to any applicable withholding and without interest thereon, upon the achievement of a regulatory milestone. The expiration of the HSR Act waiting period occurred at 11:59 p.m., New York City Time, on June 20. "Expiration of the waiting period under the HSR Act satisfies one of the conditions necessary for the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 29, 2025, among Novartis, Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis, and Regulus, including the tender offer and the subsequent merger, which remain subject to the condition that there be validly tendered and not validly withdrawn, immediately prior to the Expiration Time a number of Shares that, together with any Shares then owned by Novartis, Purchaser or any of their direct or indirect wholly owned subsidiaries, represents at least one more Share than 50% of the total number of all the outstanding Shares immediately prior to the Expiration Time. The offer will expire one minute past 11:59 p.m., New York City Time, on June 24, 2025, unless the tender offer is otherwise extended or earlier terminated," the company stated.

2 · Reply

Thomas105 Jun. 23 at 9:34 AM

$RGLS https://www.cash.ch/news/top-news/novartis-erreicht-bei-regulus-ubernahme-zwischenetappe-836014

0 · Reply

Novartis completes acquisition of Regulus Therapeutics

NVS

Jun 25, 2025, 1:00 AM EDT - 1 day ago

Novartis announces expiration of Regulus Therapeutics tender offer

NVS

May 27, 2025, 7:56 AM EDT - 4 weeks ago

Novartis announces commencement of tender offer to acquire Regulus Therapeutics

NVS

May 8, 2025, 4:05 PM EDT - 6 weeks ago

Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates

May 4, 2025, 12:25 PM EDT - 7 weeks ago

REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc. - RGLS

Apr 30, 2025, 12:24 PM EDT - 2 months ago

Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher

NVS

Apr 30, 2025, 11:22 AM EDT - 2 months ago

Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million

NVS

Apr 30, 2025, 7:50 AM EDT - 2 months ago

Novartis to Acquire Regulus in $1.7 Billion Deal

NVS

Apr 30, 2025, 7:25 AM EDT - 2 months ago

Novartis to buy Regulus Therapeutics for up to $1.7 billion

NVS

Apr 30, 2025, 7:10 AM EDT - 2 months ago

Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure

NVS

Apr 30, 2025, 7:00 AM EDT - 2 months ago

Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG

NVS

Apr 2, 2025, 8:00 AM EDT - 3 months ago

Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit

Mar 27, 2025, 12:59 PM EDT - 3 months ago

Regulus Therapeutics Stock Shoots Higher After Positive Results From Investigational Drug For Rare Type Of Kidney Disease

Mar 27, 2025, 7:00 AM EDT - 3 months ago

Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Mar 13, 2025, 4:05 PM EDT - 3 months ago

Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates

Mar 4, 2025, 8:00 AM EST - 4 months ago

Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference

Feb 4, 2025, 8:00 AM EST - 5 months ago

Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 29, 2025, 7:00 AM EST - 5 months ago

Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429)

Nov 26, 2024, 8:00 AM EST - 7 months ago

Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences

Nov 7, 2024, 4:05 PM EST - 8 months ago

Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates

Oct 8, 2024, 8:00 AM EDT - 9 months ago

Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Aug 28, 2024, 8:00 AM EDT - 10 months ago

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences

Aug 8, 2024, 4:05 PM EDT - 11 months ago

Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates

Aug 6, 2024, 8:00 AM EDT - 11 months ago

Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Jun 4, 2024, 8:00 AM EDT - 1 year ago

Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes

May 16, 2024, 8:00 AM EDT - 1 year ago

Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer

May 9, 2024, 4:05 PM EDT - 1 year ago

Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates

May 6, 2024, 8:00 AM EDT - 1 year ago

Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Apr 30, 2024, 8:00 AM EDT - 1 year ago

Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series

Apr 10, 2024, 12:51 PM EDT - 1 year ago

Regulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKD

Mar 21, 2024, 4:05 PM EDT - 1 year ago

Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates

Mar 12, 2024, 6:32 AM EDT - 1 year ago

Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity

Mar 12, 2024, 6:30 AM EDT - 1 year ago

Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Jan 2, 2024, 4:05 PM EST - 1 year ago

Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Nov 22, 2023, 8:00 AM EST - 1 year ago

Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference

Nov 9, 2023, 4:05 PM EST - 1 year ago

Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates

Nov 2, 2023, 8:00 AM EDT - 1 year ago

Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Oct 19, 2023, 8:00 AM EDT - 1 year ago

Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Sep 20, 2023, 7:00 AM EDT - 1 year ago

Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Sep 13, 2023, 8:00 AM EDT - 1 year ago

Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Aug 23, 2023, 8:00 AM EDT - 2 years ago

Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023

Aug 8, 2023, 4:05 PM EDT - 2 years ago

Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates

Aug 2, 2023, 8:00 AM EDT - 2 years ago

Regulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

Jul 18, 2023, 8:00 AM EDT - 2 years ago

Regulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney Conference

Jun 27, 2023, 8:00 AM EDT - 2 years ago

Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Jun 23, 2023, 8:00 AM EDT - 2 years ago

Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D.

Jun 20, 2023, 8:00 AM EDT - 2 years ago

Regulus Therapeutics Announces Update on Preclinical Studies in Amyotrophic Lateral Sclerosis in Collaboration with Researchers from Harvard's Brigham and Women's Hospital

BinaryLogic Jun. 26 at 2:38 AM

$VTYX $RGLS $VIGL

0 · Reply

BigBadBeethoven Jun. 25 at 6:09 PM

1 · Reply

JG101 Jun. 25 at 4:12 PM

1 · Reply

DonCorleone77 Jun. 25 at 10:59 AM

0 · Reply

Love_To_Learn Jun. 25 at 10:16 AM

$RGLS buyout went to u due to rejection from our end on our offer due to timing and special meeting that was held among many other reasons $PSTV !

0 · Reply

Thomas105 Jun. 25 at 5:58 AM

$RGLS https://www.cash.ch/news/top-news/novartis-kann-regulus-ubernahme-abschliessen-836879

0 · Reply

tradingcalendar Jun. 24 at 6:41 PM

0 · Reply

TwongStocks Jun. 23 at 8:00 PM

0 · Reply

DonCorleone77 Jun. 23 at 10:33 AM

2 · Reply

Thomas105 Jun. 23 at 9:34 AM

$RGLS https://www.cash.ch/news/top-news/novartis-erreicht-bei-regulus-ubernahme-zwischenetappe-836014

0 · Reply

ELONandTRUMP Jun. 19 at 5:35 PM

$VTYX $RGLS $VIGL What kind of engineering did you study

0 · Reply

BinaryLogic Jun. 19 at 3:55 PM

$VTYX $RGLS $VIGL [Again]

0 · Reply

BigBadBeethoven Jun. 18 at 10:27 PM

$RGLS at this point, I feel sure that the Tender offer is going to go through. So all our Shares are going to be handed over to Novartis whether we like it or not, and we're going to get seven bucks plus the CVR. In a way I'm not happy about it because I think that drug is going to be worth a lot more than seven bucks in the future. If for some reason though they don't get 50% of the shares PLUS ONE, I the price will drop really fast but I think we will get another offer in a short time that's probably going to be even higher.

0 · Reply

Pafist Jun. 18 at 4:06 PM

$RGLS Has anyone received a call in order to sell your shares? The caller said the offer ends shortly and that we are still entitled to CVR. Are you guys holding or selling?

2 · Reply

BinaryLogic Jun. 14 at 11:59 PM

$VTYX Look at $RGLS and $VIGL, then come to $VTYX and you will see that some investor(s) are consistently and continuously building here, methodically, taking the SP off of Overbought conditions then continuing to climb. Look at the product pipeline here: multiple phase-2/3 candidates across Crohn's, ulcerative colitis, Parkinson's and peridcarditis. Now-look at the financial statements. This Company has more than doubled over the last month and it is still valued under BV! Excellent acquisition target with 3-5X additional upside (IMO). https://ventyxbio.com/pipeline/

1 · Reply

LilyR Jun. 13 at 6:32 AM

$SLS For your reference in case you think about $SLS BO may happen . I received $RGLS documents regarding the BO process , some major date and negotiation process : 1,in March . 2024, $RGLS , 100 million private placement equity financing , cash runway till 1st half of 2026 2, June. 2024, 3rd cohort , positive readout / Evercore Group L.L.C as financial advisor , looking for potential strategic alternative , partnership or collaboration 3, July, 8, 2024, A company Sept, Oct. B, C, D & Novartis 4, Jan. 10,2025, A, B, C, D, E, AND Novartis Jan. 29, 2025, topline data 4th cohort , March. 17, A , offer 2.5 +0.75 CVR March. 28, A , offer 2.5+0.85 CVR April. 4, Novartis , 3+1.5 CVR April. 10, another company can offer 4 +3.5 CVR April. 15, A , 5+5 CVR April. 16, Novartis, 3.5+3.5 CVR April. 20, Novartis, 6+6 CVR April. 27, Novartis, best offer and final 7+7 CVR From the topline date 4th cohort, Jan. 29, 2025, it took RGLS about 3 months to final best offer

6 · Reply

BinaryLogic Jun. 9 at 1:37 AM

$RGLS [Again]

0 · Reply

LilyR Jun. 7 at 10:38 PM

$RGLS I am glad I bought 100,000 RGLS shares this Jan. 2025.

0 · Reply

BigBadBeethoven Jun. 6 at 7:36 PM

$RGLS if you don't tender your shares and do nothing, I suppose you will just get the $7 plus the cvr?

2 · Reply

Varus_q Jun. 6 at 10:33 AM

$RGLS – Now it’s getting interesting. We’re starting to see real appreciation of the CVRs. Everyone has now received the tender offer from Novartis, although there’s still time until June 22 to accept it. Some investors have already tendered their shares, meaning those shares are no longer available for trading. If the stock climbs into the $11–12 range, I’ll likely sell my shares rather than take the risk with the CVRs.

5 · Reply

BinaryLogic Jun. 6 at 1:04 AM

$VTYX $RGLS

0 · Reply

promela Jun. 5 at 8:16 PM

$RGLS

0 · Reply

Market Cap	564.95M
Revenue (ttm)	0.00
Net Income (ttm)	-46.36M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	9,342,400
Avg Vol	2,425,440
Day's Range	N/A - N/A
Shares Out	69.23M
Stochastic %K	72%
Beta	0.35
Analysts	Sell
Price Target	$8.80